RecruitingPhase 4NCT05730205
Effects of the Contraceptive Implant in Women With Sickle Cell Disease
Sponsor
University of Pennsylvania
Enrollment
22 participants
Start Date
Jun 8, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
The objective of this study is to measure the acceptability and impact of the progestin implant on frequency of vaso-occlusive crises, quality of life, and hematologic parameters in women with SCD.
Eligibility
Sex: FEMALEMin Age: 18 YearsMax Age: 45 Years
Inclusion Criteria7
- Female aged 18-45
- Diagnosis of sickle cell disease (SS or SB0)
- Report of at least 1 vaso-occlusive pain episode per month on average in the previous 6 months
- Willing to discontinue any hormonal contraception at the time of enrollment. Washout period of 1 month required for all hormonal contraception prior to enrollment in the study.
- Access to a device with text messaging capability
- Must be able to read and understand English
- Willing to comply with study procedures
Exclusion Criteria6
- SC Disease
- Use of Depo Provera in the past 6 months
- Changes to sickle cell medications in the past 3 months
- Contraindications to use of Nexplanon device as per clinical standards
- Currently pregnant or pregnant within the last month or seeking to become pregnant
- Currently breastfeeding
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGNexplanon 68 MG Drug Implant
Progestin contraceptive device
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05730205
Related Trials
The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
NCT0697586554 locations
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
NCT039378171 location
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
NCT0643908231 locations
Sickle Cell Disease and the Genomic and Gene Therapy Needs of Stakeholders
NCT044161781 location
Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor
NCT032143541 location